BTIG Research Cuts Tempus AI (NASDAQ:TEM) Price Target to $70.00

Tempus AI (NASDAQ:TEM) had its price target reduced by analysts at BTIG Research from $80.00 to $70.00 in a research note issued to investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. BTIG Research’s target price indicates a potential upside of 49.64% from the stock’s previous close.

Several other brokerages have also issued reports on TEM. Guggenheim increased their price target on Tempus AI from $60.00 to $65.00 and gave the stock a “buy” rating in a report on Thursday, July 16th. Jefferies Financial Group started coverage on shares of Tempus AI in a report on Monday, April 13th. They issued an “underperform” rating and a $35.00 target price on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Tempus AI in a report on Wednesday, June 17th. Needham & Company LLC reiterated a “buy” rating and issued a $75.00 target price on shares of Tempus AI in a report on Friday. Finally, Freedom Capital upgraded shares of Tempus AI to a “hold” rating in a report on Tuesday, June 30th. Nine investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Tempus AI presently has a consensus rating of “Hold” and an average target price of $66.77.

Tempus AI Trading Up 6.6%

TEM stock traded up $2.91 during mid-day trading on Monday, reaching $46.78. The company’s stock had a trading volume of 3,460,338 shares, compared to its average volume of 5,875,114. The company has a market cap of $8.40 billion, a price-to-earnings ratio of -32.47 and a beta of 3.58. Tempus AI has a 12 month low of $40.77 and a 12 month high of $104.32. The business’s 50 day moving average price is $51.40 and its 200 day moving average price is $52.59. The company has a current ratio of 3.30, a quick ratio of 3.16 and a debt-to-equity ratio of 3.06.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings data on Thursday, July 30th. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.10. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The company had revenue of $382.49 million during the quarter, compared to analyst estimates of $379.69 million. During the same quarter in the previous year, the business posted ($0.22) EPS. Tempus AI’s revenue for the quarter was up 21.6% compared to the same quarter last year. On average, equities research analysts predict that Tempus AI will post -1.35 EPS for the current year.

Insider Activity at Tempus AI

In other news, EVP Andrew Polovin sold 8,703 shares of the stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $44.07, for a total transaction of $383,541.21. Following the completion of the transaction, the executive vice president directly owned 128,215 shares of the company’s stock, valued at $5,650,435.05. This represents a 6.36% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO James William Rogers sold 11,529 shares of Tempus AI stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $55.00, for a total transaction of $634,095.00. Following the completion of the sale, the chief financial officer directly owned 114,866 shares in the company, valued at $6,317,630. This trade represents a 9.12% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 699,793 shares of company stock worth $33,763,231 in the last ninety days. Corporate insiders own 24.26% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Aberdeen Group plc raised its position in shares of Tempus AI by 64.2% in the fourth quarter. Aberdeen Group plc now owns 263,004 shares of the company’s stock valued at $15,530,000 after purchasing an additional 102,878 shares during the period. Pictet Asset Management Holding SA grew its stake in Tempus AI by 291.3% in the 4th quarter. Pictet Asset Management Holding SA now owns 48,488 shares of the company’s stock valued at $2,948,000 after buying an additional 36,096 shares in the last quarter. Bogart Wealth LLC lifted its position in shares of Tempus AI by 365,087.5% during the fourth quarter. Bogart Wealth LLC now owns 58,430 shares of the company’s stock worth $3,450,000 after acquiring an additional 58,414 shares in the last quarter. Eagle Health Investments LP purchased a new stake in shares of Tempus AI during the first quarter worth $11,588,000. Finally, Alethea Capital Management LLC bought a new stake in shares of Tempus AI during the 4th quarter valued at $1,863,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.